Authors

Latest:

Dr. Savin on the Challenges of Developing Biosimilar Clinical Trials

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.

Michael A. Thompson

Latest:

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.

Michael A. Thompson, MD, PhD

Latest:

Dr. Thompson on the Future of Treatment in Multiple Myeloma

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Michael Aberger, MD

Latest:

Dr. Aberger Discusses a Cost Analysis of Testicular Self-Examinations

Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.

Michael Andreeff, MD, PhD

Latest:

Dr Andreeff on the Rationale for Investigating Uproleselan Plus Venetoclax and Azacitidine in AML

Michael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Michael B. Atkins, MD

Latest:

Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma

Michael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.

Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center

Latest:

Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE Study

Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.

Michael Birrer, MD, ONeal Comprehensive Cancer Center

Michael Birrer, MD, PhD

Latest:

Dr Birrer on the Potential Utility of ADCs in Platinum-Resistant Ovarian Cancer

Michael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.

Michael Bouvet, MD

Latest:

Dr. Bouvet Discusses Risk Factors for Thyroid Cancer

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses risk factors for thyroid cancer.

Michael Brawer, MD

Latest:

Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Michael Broderson

Latest:

Management of Patients with Cancer

Michael Broderson, PharmD, Nebraska Cancer Specialists, discusses the management of patients with cancer.

Michael Choi, MD

Latest:

Dr Choi on the Implications of Approving Liso-Cel in Patients With CLL

Michael Choi, MD, discusses the potential FDA approval of lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Michael Choi, MD, UC San Diego Medical Center

Latest:

Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLL

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.

Michael Cookson, MD

Latest:

Dr. Cookson on Understanding Predictive Features in the Management of Prostate Cancer

Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.

Michael D. Alvarado, MD, University of California San Francisco

Michael D. Becker

Latest:

Tech Sectors: Biotechnology: The Treatment of Palmar-plantar Erythrodysesthesia

A potential new candidate uses uracil to combat this cancer treatment side effect.

Michael D. Fabrizio, MD, FACS, Eastern Virginia Medical School

Michael D. Mix, MD

Latest:

Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLC

Michael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).

Michael D. Offin, MD

Latest:

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.